CA1224145A - Sang synthetique a base de gelatine et procede de preparation - Google Patents

Sang synthetique a base de gelatine et procede de preparation

Info

Publication number: CA1224145A
Authority: CA; Canada
Prior art keywords: gelatin; volume; weight; phase; coacervate
Prior art date: 1982-10-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000503072A

Other languages

English (en)

Inventor

Charles S. Ecanow

Bernard Ecanow

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Neomed Corp

Original Assignee

Neomed Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-10-29

Filing date

1986-02-28

Publication date

1987-07-14

1983-02-07 Priority claimed from US06/464,704 external-priority patent/US4539204A/en

1986-02-28 Application filed by Neomed Corp filed Critical Neomed Corp

1986-02-28 Priority to CA000503072A priority Critical patent/CA1224145A/fr

1987-07-14 Application granted granted Critical

1987-07-14 Publication of CA1224145A publication Critical patent/CA1224145A/fr

Status Expired legal-status Critical Current

Links

108010010803 Gelatin Proteins 0.000 title claims abstract description 80
235000019322 gelatine Nutrition 0.000 title claims abstract description 80
235000011852 gelatine desserts Nutrition 0.000 title claims abstract description 80
229920000159 gelatin Polymers 0.000 title claims abstract description 78
239000008273 gelatin Substances 0.000 title claims abstract description 75
238000004519 manufacturing process Methods 0.000 title claims abstract description 15
210000004369 blood Anatomy 0.000 title abstract description 45
239000008280 blood Substances 0.000 title abstract description 45
239000000203 mixture Substances 0.000 claims abstract description 73
108010001708 stroma free hemoglobin Proteins 0.000 claims abstract description 60
238000000034 method Methods 0.000 claims abstract description 51
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 24
239000000787 lecithin Substances 0.000 claims abstract description 24
229940067606 lecithin Drugs 0.000 claims abstract description 24
235000010445 lecithin Nutrition 0.000 claims abstract description 24
239000012530 fluid Substances 0.000 claims abstract description 14
239000000654 additive Substances 0.000 claims abstract description 11
239000000126 substance Substances 0.000 claims abstract description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
230000008569 process Effects 0.000 claims description 18
239000000243 solution Substances 0.000 claims description 18
239000003633 blood substitute Substances 0.000 claims description 15
102000004190 Enzymes Human genes 0.000 claims description 11
108090000790 Enzymes Proteins 0.000 claims description 11
239000003792 electrolyte Substances 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 8
229940079593 drug Drugs 0.000 claims description 8
235000015097 nutrients Nutrition 0.000 claims description 8
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
230000000996 additive effect Effects 0.000 claims description 6
239000002245 particle Substances 0.000 claims description 6
102000004169 proteins and genes Human genes 0.000 claims description 6
108090000623 proteins and genes Proteins 0.000 claims description 6
239000002563 ionic surfactant Substances 0.000 claims description 5
239000002736 nonionic surfactant Substances 0.000 claims description 4
239000002504 physiological saline solution Substances 0.000 claims description 4
229910052708 sodium Inorganic materials 0.000 claims description 4
239000011734 sodium Substances 0.000 claims description 4
235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
239000007864 aqueous solution Substances 0.000 claims description 2
238000004945 emulsification Methods 0.000 claims description 2
229910052700 potassium Inorganic materials 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
238000010979 pH adjustment Methods 0.000 claims 5
239000003960 organic solvent Substances 0.000 claims 2
230000001225 therapeutic effect Effects 0.000 claims 2
239000002502 liposome Substances 0.000 abstract description 17
239000007788 liquid Substances 0.000 abstract description 13
108010057694 modified fluid gelatins Proteins 0.000 abstract description 4
229940074308 modified fluid gelatins Drugs 0.000 abstract description 4
229940014259 gelatin Drugs 0.000 description 63
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 24
229910052760 oxygen Inorganic materials 0.000 description 24
239000001301 oxygen Substances 0.000 description 24
238000002360 preparation method Methods 0.000 description 23
108010054147 Hemoglobins Proteins 0.000 description 16
102000001554 Hemoglobins Human genes 0.000 description 16
230000032258 transport Effects 0.000 description 13
102000009027 Albumins Human genes 0.000 description 11
108010088751 Albumins Proteins 0.000 description 11
239000000839 emulsion Substances 0.000 description 9
235000011121 sodium hydroxide Nutrition 0.000 description 8
229940083608 sodium hydroxide Drugs 0.000 description 8
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
231100000252 nontoxic Toxicity 0.000 description 5
230000003000 nontoxic effect Effects 0.000 description 5
239000012153 distilled water Substances 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
210000002381 plasma Anatomy 0.000 description 4
238000003860 storage Methods 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
230000008901 benefit Effects 0.000 description 3
229910002092 carbon dioxide Inorganic materials 0.000 description 3
239000000084 colloidal system Substances 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
235000020776 essential amino acid Nutrition 0.000 description 3
239000003797 essential amino acid Substances 0.000 description 3
239000007789 gas Substances 0.000 description 3
238000005534 hematocrit Methods 0.000 description 3
230000003204 osmotic effect Effects 0.000 description 3
229940083542 sodium Drugs 0.000 description 3
235000015424 sodium Nutrition 0.000 description 3
238000012546 transfer Methods 0.000 description 3
239000004606 Fillers/Extenders Substances 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
230000009850 completed effect Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
229960001407 sodium bicarbonate Drugs 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
101710169603 Hemoglobin-1 Proteins 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000012891 Ringer solution Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000009582 blood typing Methods 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
150000005829 chemical entities Chemical class 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000008098 formaldehyde solution Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
102000018146 globin Human genes 0.000 description 1
108060003196 globin Proteins 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
108010036302 hemoglobin AS Proteins 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000867 polyelectrolyte Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011369 resultant mixture Substances 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1

Landscapes

Medicinal Preparation (AREA)

CA000503072A 1982-10-29 1986-02-28 Sang synthetique a base de gelatine et procede de preparation Expired CA1224145A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000503072A CA1224145A (fr)	1982-10-29	1986-02-28	Sang synthetique a base de gelatine et procede de preparation

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US43782382A	1982-10-29	1982-10-29
US437,823		1982-10-29
US464,704		1983-02-07
US06/464,704 US4539204A (en)	1982-10-29	1983-02-07	Gelatin based synthetic blood and a method of making the same
CA000428347A CA1206093A (fr)	1982-10-29	1983-05-17	Sang entier synthetique a base de gelatine et methode de preparation
CA000503072A CA1224145A (fr)	1982-10-29	1986-02-28	Sang synthetique a base de gelatine et procede de preparation

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000428347A Division CA1206093A (fr)	1982-10-29	1983-05-17	Sang entier synthetique a base de gelatine et methode de preparation

Publications (1)

Publication Number	Publication Date
CA1224145A true CA1224145A (fr)	1987-07-14

Family

ID=27167345

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000503072A Expired CA1224145A (fr)	1982-10-29	1986-02-28	Sang synthetique a base de gelatine et procede de preparation

Country Status (1)

Country	Link
CA (1)	CA1224145A (fr)

1986
- 1986-02-28 CA CA000503072A patent/CA1224145A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2004-07-14	MKEX	Expiry

Publication	Publication Date	Title
US4963526A (en)	1990-10-16	Oral insulin and a method of making the same
US4849405A (en)	1989-07-18	Oral insulin and a method of making the same
US4133874A (en)	1979-01-09	Lipid encapsulated hemoglobin cells
US4794000A (en)	1988-12-27	Coacervate-based oral delivery system for medically useful compositions
US4423077A (en)	1983-12-27	Perfluorochemical emulsion artificial blood
US4425334A (en)	1984-01-10	Functional oxygen transport system
US4343797A (en)	1982-08-10	Synthetic whole blood and a method of making the same
WO1985005029A1 (fr)	1985-11-21	Insuline administree par voie orale et son procede de preparation
EP0124527B1 (fr)	1987-08-12	Sang entier synthetique a base de gelatine et son procede de fabrication
US5589189A (en)	1996-12-31	Liposome dispersion
US4439424A (en)	1984-03-27	Synthetic whole blood
US4547490A (en)	1985-10-15	Synthetic whole blood and a method of making the same
JPH0720857B2 (ja)	1995-03-08	リポソームおよびその製法
US4497829A (en)	1985-02-05	Process for preparing perfluorochemical emulsion artificial blood
US4596788A (en)	1986-06-24	Gelatin and lecithin based synthetic whole blood and a method of making the same
US4738952A (en)	1988-04-19	Substitute for human blood and a method of making the same
Farmer et al.	1988	Liposome-encapsulated hemoglobin: oxygen binding properties and respiratory function
EP0416575A2 (fr)	1991-03-13	Compositions pour la délivrance de médicaments à base de substances biologiques et procédé de préparation de telles compositions
US4558032A (en)	1985-12-10	Synthetic whole blood substitute and a method of making the same
US5693336A (en)	1997-12-02	Blood stable liposomal cyclosporin formulations
Zheng et al.	1993	Hemoglobin multiple emulsion as an oxygen delivery system
AU583272B2 (en)	1989-04-27	Coacervate system synthetic whole blood substitute
JPS58502204A (ja)	1983-12-22	合成全血およびその製造方法
US4853370A (en)	1989-08-01	Substitute for human blood and a method of making the same
EP0223906A2 (fr)	1987-06-03	Sang entier synthétique à base de gélatine et son procédé de fabrication